1-9 of 9
Eunice L. Kwak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors

David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2403–2413.
https://doi.org/10.1158/1078-0432.CCR-18-1341
Published: 15 April 2019
View article titled, Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Dejan Juric, Johann S. de Bono, Patricia M. LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, Teresa Macarulla Mercadé, Elena Geuna, Maria Jose de Miguel-Luken, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (17): 5015–5023.
https://doi.org/10.1158/1078-0432.CCR-16-2888
Published: 31 August 2017
View article titled, A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Open the PDF for A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, Johanna Bendell, James Spicer, Eunice L. Kwak, Susan S. Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, Maria Alsina, Irene Braña, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1888–1895.
https://doi.org/10.1158/1078-0432.CCR-14-1306
Published: 14 April 2015
View article titled, First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Open the PDF for First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1884–1890.
https://doi.org/10.1158/1078-0432.CCR-13-2649
Published: 31 March 2014
View article titled, Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L. Kwak, Jose Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Egile, Gerald Edelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 233–245.
https://doi.org/10.1158/1078-0432.CCR-13-1777
Published: 05 January 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis

Kofi Asomaning, Amy E. Reid, Wei Zhou, Rebecca S. Heist, Rihong Zhai, Li Su, Eunice L. Kwak, Lawrence Blaszkowsky, Andrew X. Zhu, David P. Ryan, David C. Christiani, Geoffrey Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 4010–4015.
https://doi.org/10.1158/1078-0432.CCR-07-4187
Published: 16 June 2008
View article titled, MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis
Open the PDF for MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis in another window
Journal Articles

Targeted Agents: The Rules of Combination

Eunice L. Kwak, Jeffrey W. Clark, Bruce Chabner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (18): 5232–5237.
https://doi.org/10.1158/1078-0432.CCR-07-1385
Published: 17 September 2007
View article titled, Targeted Agents: The Rules of Combination
Open the PDF for Targeted Agents: The Rules of Combination in another window
Journal Articles

Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas

Eunice L. Kwak, Janusz Jankowski, Sarah P. Thayer, Gregory Y. Lauwers, Brian W. Brannigan, Patricia L. Harris, Ross A. Okimoto, Sara M. Haserlat, David R. Driscoll, David Ferry, Beth Muir, Jeff Settleman, Charles S. Fuchs, Matthew H. Kulke, David P. Ryan, Jeff W. Clark, Dennis C. Sgroi, Daniel A. Haber, Daphne W. Bell
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4283–4287.
https://doi.org/10.1158/1078-0432.CCR-06-0189
Published: 20 July 2006
View article titled, Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
Open the PDF for Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas in another window